Pipeline

 

A Novel Approach of Selectively Targeting Pathogenic Immune Cells

We are rapidly advancing a potential therapy for the treatment of Type 1 Diabetes through partnerships with Pfizer, Inc. and JDRF and are advancing pre-clinical programs in a number of other auto-immune related diseases, including Rheumatoid Arthritis, Psoriasis, Inflammatory Bowel Disease, Celiac Disease, Myasthenia Gravis, and Multiple Sclerosis.